ABSK-051

N/A

Report date: 2023/11/01 16:08:12
NME

Base Information

Drug NameABSK-051
Drug Alias NameABSK051
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5'-nucleotidase inhibitors
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesABbisko Therapeutics Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A